Skip to main content
EVO
NASDAQ Life Sciences

Evotec SE Reports New 5.03% Stake by Michael Kaufman and Triton's Increased Holding to 9.97%

KI-Analyse von Wiseek
Stimmung info
Positiv
Wichtigkeit info
8
Preis
$3.76
Marktkapitalisierung
$1.339B
52W Tief
$2.84
52W Hoch
$4.8
Market data snapshot near publication time

summarizeZusammenfassung

These filings indicate strong institutional interest and conviction in Evotec SE. The emergence of Michael Kaufman's entities as a new 5.03% shareholder, combining direct shares and equity swaps, signals fresh investor confidence. Concurrently, Triton GP HoldCo SARL, an existing major investor, increased its stake to nearly 10% and appears to have converted previous instrument holdings into direct shares, further solidifying its commitment. Such significant accumulation by institutional investors can be a positive indicator for the company's future prospects.


check_boxSchlusselereignisse

  • Michael Kaufman's Entities Disclose New 5.03% Stake

    Michael Kaufman and associated entities, including MAK Capital Fund LP, reported a new aggregate holding of 5.03% of Evotec SE's voting rights, comprising 2.89% in direct shares and 2.14% through equity swaps. This represents a significant new institutional investment.

  • Triton Increases Stake to 9.97%

    Triton GP HoldCo SARL, a private equity firm and existing major investor, increased its total holding in Evotec SE to 9.97% of voting rights, up from a previously reported 9.16%. The new filing indicates that the entire stake is now held as direct voting rights, suggesting a conversion of prior instrument holdings to direct shares, which demonstrates increased commitment.


auto_awesomeAnalyse

These filings indicate strong institutional interest and conviction in Evotec SE. The emergence of Michael Kaufman's entities as a new 5.03% shareholder, combining direct shares and equity swaps, signals fresh investor confidence. Concurrently, Triton GP HoldCo SARL, an existing major investor, increased its stake to nearly 10% and appears to have converted previous instrument holdings into direct shares, further solidifying its commitment. Such significant accumulation by institutional investors can be a positive indicator for the company's future prospects.

Zum Zeitpunkt dieser Einreichung wurde EVO bei 3,76 $ gehandelt an der NASDAQ im Sektor Life Sciences, bei einer Marktkapitalisierung von rund 1,3 Mrd. $. Die 52-Wochen-Handelsspanne lag zwischen 2,84 $ und 4,80 $. Diese Einreichung wurde mit positiver Marktstimmung und einem Wichtigkeitsscore von 8 von 10 bewertet.

descriptionHaupt-SEC-Einreichung ansehen

show_chartPreisdiagramm

Diesen Artikel teilen

Copied!

feed EVO - Neueste Einblicke

EVO
Apr 24, 2026, 6:03 AM EDT
Filing Type: 6-K
Importance Score:
7
EVO
Apr 08, 2026, 11:56 AM EDT
Filing Type: 6-K
Importance Score:
8
EVO
Apr 08, 2026, 11:52 AM EDT
Filing Type: 20-F
Importance Score:
8
EVO
Apr 07, 2026, 12:44 PM EDT
Filing Type: 6-K
Importance Score:
9
EVO
Apr 06, 2026, 12:56 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
9
EVO
Mar 30, 2026, 8:29 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
EVO
Mar 10, 2026, 6:00 AM EDT
Filing Type: 6-K
Importance Score:
9
EVO
Jan 16, 2026, 7:00 AM EST
Filing Type: 6-K
Importance Score:
7
EVO
Jan 13, 2026, 7:32 AM EST
Filing Type: 6-K
Importance Score:
8
EVO
Jan 08, 2026, 10:09 AM EST
Filing Type: 6-K
Importance Score:
7